Lowell Farms Past Earnings Performance
Past criteria checks 0/6
Lowell Farms has been growing earnings at an average annual rate of 2.1%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 1.1% per year.
Key information
2.1%
Earnings growth rate
41.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 1.1% |
| Return on equity | -420.1% |
| Net Margin | -141.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lowell Farms makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 26 | -36 | 9 | 0 |
| 31 Dec 23 | 28 | -37 | 10 | 0 |
| 30 Sep 23 | 30 | -35 | 10 | 0 |
| 30 Jun 23 | 33 | -20 | 11 | 0 |
| 31 Mar 23 | 39 | -25 | 13 | 0 |
| 31 Dec 22 | 44 | -25 | 15 | 0 |
| 30 Sep 22 | 49 | -23 | 17 | 0 |
| 30 Jun 22 | 53 | -27 | 20 | 0 |
| 31 Mar 22 | 55 | -22 | 22 | 0 |
| 31 Dec 21 | 54 | -25 | 22 | 0 |
| 30 Sep 21 | 48 | -19 | 21 | 0 |
| 30 Jun 21 | 49 | -11 | 20 | 0 |
| 31 Mar 21 | 44 | -21 | 16 | 0 |
| 31 Dec 20 | 43 | -22 | 17 | 0 |
| 30 Sep 20 | 44 | -35 | 23 | 0 |
| 30 Jun 20 | 40 | -54 | 27 | 0 |
| 31 Mar 20 | 40 | -53 | 33 | 0 |
| 31 Dec 19 | 37 | -50 | 32 | 0 |
| 30 Sep 19 | 33 | -36 | 25 | 0 |
| 30 Jun 19 | 28 | -17 | 19 | 0 |
| 31 Mar 19 | 21 | -11 | 13 | 0 |
| 31 Dec 18 | 17 | -9 | 11 | 0 |
| 31 Dec 17 | 15 | -7 | 8 | 0 |
| 31 Dec 16 | 5 | -3 | 4 | 0 |
Quality Earnings: 2WU is currently unprofitable.
Growing Profit Margin: 2WU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2WU is unprofitable, but has reduced losses over the past 5 years at a rate of 2.1% per year.
Accelerating Growth: Unable to compare 2WU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2WU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 2WU has a negative Return on Equity (-420.09%), as it is currently unprofitable.